- \n
- Updated ACS guideline offers Shield as a new choice for over 50 million eligible Americans who are not up to date with their colorectal cancer screening<\/i><\/li>\n
- Shield is the first and only FDA-approved blood test included in both ACS and NCCN guidelines<\/i><\/li>\n<\/ul>\n
PALO ALTO, Calif.–(BUSINESS WIRE<\/a>)–
\nGuardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced that its FDA-approved Shield\u2122 blood test is now included in updated American Cancer Society (ACS) Colorectal Cancer (CRC) Screening Guidelines published today. The major screening guideline update recommends Shield as a choice for patients who decline or have not completed stool-based or visual examination screening tests.<\/p>\n\nIn an effort to address persistent screening gaps and rising CRC rates in adults under 65, ACS guidelines now recommend Shield blood-based CRC screening as a new option to expand access and screening participation. Shield is the first and only FDA-approved blood test for primary colorectal cancer screening in average-risk adults age 45 and older and can be completed with just a blood draw during a routine doctor\u2019s visit.<\/p>\n
\nCRC is the second leading cancer killer in the United States1<\/sup> and the number one cancer killer for adults under 50.2<\/sup> The inclusion of Shield in the updated guidelines acknowledges a central challenge in colorectal cancer screening: more than 50 million eligible adults3<\/sup> remain unscreened despite established methods like colonoscopy or stool-based testing existing for decades. By recognizing the effectiveness of a blood-based option, the updated guidelines add a new opportunity to reach patients who might otherwise go unscreened.<\/p>\n
\nWith three out of four CRC deaths among those not up to date with screening4<\/sup>, the American Cancer Society noted that \u201coffering multiple, recommended screening options supports informed patient choice and may improve participation, because the most effective screening test is the one that the patient completes.<\/b>\u201d<\/p>\n
\n\u201cThe inclusion of Shield in the American Cancer Society\u2019s guidelines as a recommended option is a momentous step forward in our collective work to reach the more than 50 million Americans who remain unscreened for colorectal cancer,\u201d said AmirAli Talasaz, Guardant Health co-CEO. \u201cWe know that tragically cancer does not wait. The Shield blood test has been proven to be effective in detecting cancers and increasing screening participation in the real-world setting. By making colorectal cancer screening more accessible with a blood-based option in conjunction with other established methodologies, we can get people screened.\u201d<\/p>\n
\nGuardant\u2019s Shield blood test stood out in guideline evidence for having the highest screening adherence rate compared to traditional colonoscopies and stool-based tests.5<\/sup> In the real-world experience with approximately 200,000 patients tested, Shield is proven to increase screening rates with over 90% of patients completing the test.6<\/sup> In the pivotal ECLIPSE study, Shield showed its high sensitivity in detecting colorectal cancers and demonstrated sensitivity of 100% in detecting stage II and above cancers.7<\/sup><\/p>\n
\n\u201cScreening rates have been largely stagnant across the population, with particular challenges in delivering screening to younger individuals age 45 to 55, racial and ethnic minoritized groups, and individuals with lower socioeconomic position. By providing the choice of a new CRC screening modality, blood-based testing has the potential to expand the reach of CRC screening to individuals who might otherwise remain unscreened,\u201d said Samir Gupta, MD, Professor of Medicine at the University of California San Diego. \u201cToday\u2019s guideline update reflects the continued evolution of CRC screening-related technological advances, outlines persistent gaps in screening participation, and the potential for advances like blood-based testing to increase screening uptake.\u201d<\/p>\n
\nDemonstrating strong real-world evidence and clinical performance published in the New England Journal of Medicine (NEJM)7<\/sup>, Shield is the only FDA-approved blood test included in both ACS and National Comprehensive Cancer Network (NCCN) guidelines.<\/p>\n
\n\u201cThe new ACS guidelines recognize that colorectal cancer screening is not one size fits all. Patients have several screening options, and their choices are impacted by where they live, their access to care, financial pressures, personal preferences, and individual risk factors,\u201d said Anjee Davis, MPPA, CEO at Fight Colorectal Cancer. \u201cAs options expand, Fight CRC remains committed to patients making an informed choice, providing clear education, and ensuring timely follow up so more people can complete lifesaving screening. Our shared goal is clear: achieving 80% screening rates in every community.\u201d<\/p>\n
\n\u201cPresenting patients with options helps them make educated health decisions,\u201d said Chris Evans, President of the Colon Cancer Coalition. \u201cThe introduction of a blood-based choice for colorectal cancer screening will increase screening rates and ultimately save lives.\u201d<\/p>\n
\nACS guidelines for colorectal cancer screening were last updated in 2018 to lower the recommended age for screening for adults at average risk from 50 to 45 in response to the rising rate of CRC among younger adults.<\/p>\n
About Shield<\/b><\/p>\n
\nShield is a methylation partitioning cell-free DNA (mp-cfDNA) non-invasive, blood-based screening test that detects alterations associated with colorectal cancer in the blood. It is intended as a screening test for individuals at average risk for the disease, age 45 or older, and is not intended for individuals at high risk for colorectal cancer. The Shield test can be considered in a manner similar to guideline-recommended non-invasive CRC screening options and can be completed during any healthcare visit. A positive Shield result raises concern for the presence of colorectal cancer or advanced adenoma and the patient should be referred for colonoscopy evaluation.<\/p>\n
About Guardant Health<\/b><\/p>\n
\nGuardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.<\/p>\n
Guardant Health Forward-Looking Statements<\/b><\/p>\n
\nThis press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health\u2019s liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health\u2019s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions \u201cRisk Factors\u201d and \u201cManagement\u2019s Discussion and Analysis of Financial Condition and Results of Operation\u201d and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2025 and in its other reports filed with or furnished to the Securities and Exchange Commission. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health\u2019s views as of any date subsequent to the date of this press release.<\/p>\n
1<\/sup> American Cancer Society. Key Statistics for Colorectal Cancer. Accessed online February 9, 2026. https:\/\/www.cancer.org\/cancer\/types\/colon-rectal-cancer\/about\/key-statistics.html<\/a><\/p>\n
2<\/sup> Scientific American. Colon cancer is killing more young people in the U.S. than any other cancer. January 22, 2026. https:\/\/www.scientificamerican.com\/article\/colon-cancer-is-killing-more-young-people-in-the-u-s-than-any-other-cancer\/<\/a><\/p>\n
3<\/sup> American Cancer Society National Colorectal Cancer Roundtable. Colorectal Cancer Is A Major Public Health Problem. https:\/\/nccrt.org\/our-impact\/data-and-progress\/<\/a>.<\/p>\n
4<\/sup> Doubeni, C, et al. Modifiable Failures in the Colorectal Cancer Screening Process and Their Association with Risk of Death. Gastroenterology. 2019 Jan; 156(1): 63\u201374.e6.<\/p>\n
5<\/sup> Cullison J. A blood-based test for colorectal cancer screening. HCA Healthc J Med.<\/i> 2025;6(6):571-573. doi:10.36518\/2689-0216.2259.<\/p>\n
6<\/sup> Graham-Adderton, C., Guerra, C. E., Ngo-Metzger, Q., Hoang, T., & Raymond, V. M. (2025). Implementation of blood-based colorectal cancer screening: Real-world adherence and outcomes.<\/p>\n
7<\/sup> Chung, D. C., Gray, D. M., II, Singh, H., Issaka, R. B., Raymond, V. M., Eagle, C., Hu, S., et al. (2024). A cell-free DNA blood-based test for colorectal cancer screening<\/i>. New England Journal of Medicine, 390<\/i>(11), 973\u2013983. https:\/\/doi.org\/10.1056\/NEJMoa2304714<\/a><\/p>\n
<\/p>\n
View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20260526499046\/en\/<\/a><\/span><\/p>\n
Investor Contact:
\n<\/b>
Zarak Khurshid
\n
investors@guardanthealth.com
\n<\/a><\/p>\nMedia Contact:
\n<\/b>
Meaghan Smith
\n
press@guardanthealth.com<\/a><\/p>\nKEYWORDS:<\/b> United States North America California<\/p>\n
INDUSTRY KEYWORDS:<\/b> Technology FDA Professional Services Software Health Data Analytics General Health Artificial Intelligence Oncology<\/p>\n
- Shield is the first and only FDA-approved blood test included in both ACS and NCCN guidelines<\/i><\/li>\n<\/ul>\n
![\"Logo\"](\"https:\/\/mms.businesswire.com\/media\/20260526499046\/en\/2768869\/3\/GuardantHealthMasterLogo_ND_RGB%403x.jpg\")
<\/td>\n<\/tr>\n